Dermatomyositis (DM) is an idiopathic inflammatory myopathy that affects the skin, skeletal muscles, lungs, and other organs, resulting in various systemic manifestations.[1] Clinically amyopathic dermatomyositis (CADM) is a distinct subtype of DM characterized by typical DM cutaneous findings but with minimal or no evidence of myositis.[2] Anti-melanoma differentiation-associated gene 5 (MDA5) antibodies were originally identified to be associated with CADM in combination with rapidly progressive interstitial lung disease (RP-ILD). The gene discussed is IFIH1; the disease is dermatomyositis.